Influence of a treatment with a BRAF inhibitor and a MEK inhibitor on miR-193a-3p expression. miR-193a-3p expression was measured in a BRAF-mutant cell line RKO (left panel) and a KRAS-mutant cell line HCT116 (right panel) treated with a BRAF inhibitor dabrafenib (D-5699, LC laboratories, MA, USA) and a MEK inhibitor trametinib (16,292, Cayman Chemical Company, MI, USA) in multiple timepoints and multiple doses. Data are obtained from two independent experiments. (PPTX 138Â kb